5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1

Alexander Maslov, M. Lee, M. Gundry, S. Gravina, N. Strogonova, C. Tazearslan, A. Bendebury, Yousin Suh, Jan Vijg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2′-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces γ-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of γ-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment.

Original languageEnglish (US)
Pages (from-to)5172-5179
Number of pages8
JournalOncogene
Volume31
Issue number50
DOIs
StatePublished - Dec 13 2012

Fingerprint

decitabine
Gene Rearrangement
Methyltransferases
Genome
DNA
Point Mutation
DNA Repair

Keywords

  • 5-aza-20-deoxycytidine
  • DNA methylation
  • DNMT1
  • genome rearrangements
  • mutations

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Maslov, A., Lee, M., Gundry, M., Gravina, S., Strogonova, N., Tazearslan, C., ... Vijg, J. (2012). 5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene, 31(50), 5172-5179. https://doi.org/10.1038/onc.2012.9

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1. / Maslov, Alexander; Lee, M.; Gundry, M.; Gravina, S.; Strogonova, N.; Tazearslan, C.; Bendebury, A.; Suh, Yousin; Vijg, Jan.

In: Oncogene, Vol. 31, No. 50, 13.12.2012, p. 5172-5179.

Research output: Contribution to journalArticle

Maslov, A, Lee, M, Gundry, M, Gravina, S, Strogonova, N, Tazearslan, C, Bendebury, A, Suh, Y & Vijg, J 2012, '5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1', Oncogene, vol. 31, no. 50, pp. 5172-5179. https://doi.org/10.1038/onc.2012.9
Maslov A, Lee M, Gundry M, Gravina S, Strogonova N, Tazearslan C et al. 5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene. 2012 Dec 13;31(50):5172-5179. https://doi.org/10.1038/onc.2012.9
Maslov, Alexander ; Lee, M. ; Gundry, M. ; Gravina, S. ; Strogonova, N. ; Tazearslan, C. ; Bendebury, A. ; Suh, Yousin ; Vijg, Jan. / 5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1. In: Oncogene. 2012 ; Vol. 31, No. 50. pp. 5172-5179.
@article{fb5ce380fa254328836d554c89b5da99,
title = "5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1",
abstract = "Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2′-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces γ-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of γ-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment.",
keywords = "5-aza-20-deoxycytidine, DNA methylation, DNMT1, genome rearrangements, mutations",
author = "Alexander Maslov and M. Lee and M. Gundry and S. Gravina and N. Strogonova and C. Tazearslan and A. Bendebury and Yousin Suh and Jan Vijg",
year = "2012",
month = "12",
day = "13",
doi = "10.1038/onc.2012.9",
language = "English (US)",
volume = "31",
pages = "5172--5179",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "50",

}

TY - JOUR

T1 - 5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1

AU - Maslov, Alexander

AU - Lee, M.

AU - Gundry, M.

AU - Gravina, S.

AU - Strogonova, N.

AU - Tazearslan, C.

AU - Bendebury, A.

AU - Suh, Yousin

AU - Vijg, Jan

PY - 2012/12/13

Y1 - 2012/12/13

N2 - Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2′-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces γ-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of γ-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment.

AB - Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2′-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces γ-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of γ-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment.

KW - 5-aza-20-deoxycytidine

KW - DNA methylation

KW - DNMT1

KW - genome rearrangements

KW - mutations

UR - http://www.scopus.com/inward/record.url?scp=84871195942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871195942&partnerID=8YFLogxK

U2 - 10.1038/onc.2012.9

DO - 10.1038/onc.2012.9

M3 - Article

C2 - 22349820

AN - SCOPUS:84871195942

VL - 31

SP - 5172

EP - 5179

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 50

ER -